System, device and method for safeguarding the wellbeing of patients for fluid injection

Patent metadata

Field	Value
Publication number	US-11896352-B2
Application number	US-202117921245-A
Country	US
Kind code	B2
Filing date	Apr 30, 2021
Priority date	Apr 30, 2020
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

A system and method for promoting and safeguarding the wellbeing of patients in relation to a fluid injection may obtain patient data; determine, based on the patient data, an initial risk prediction for a patient for a fluid injection to be administered to the patient, the initial risk prediction including a probability that the patient experiences at least one adverse event in response to the fluid injection; provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction; determine, after the fluid injection is started, sensor data associated with the patient; determine, based on the sensor data determined after the fluid injection is started, a current risk prediction including a probability that the patient experiences the at least one adverse event in response to the fluid injection; and provide, to the user device, the current risk prediction.

First claim

What is claimed is:

1. A system comprising:
at least one processor programmed and/or configured to:
obtain patient data associated with a patient;
determine, based on the patient data, an initial risk prediction for the patient associated with a fluid injection to be administered to the patient, wherein the initial risk prediction includes a probability that the patient experiences at least one adverse event in response to the fluid injection, and wherein the at least one adverse event includes: an extravasation, a post-contrast acute kidney injury, an acute adverse event, a contrast media induced nephrotoxicity, and a thyrotoxicosis such that the initial risk prediction includes a probability that the patient experiences the extravasation, a probability that the patient experiences the post-contrast acute kidney injury, a probability that the patient experiences the acute adverse event, a probability that the patient experiences the contrast media induced nephrotoxicity, and a probability that the patient experiences the thyrotoxicosis;
provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction, wherein the initial risk prediction further includes at least one of: a prompt to administer a medication to the patient before the fluid injection, a prompt to adjust an injection protocol for the fluid injection, a prompt to adjust an imaging protocol for an imaging scan, a prompt to prepare the patient before the fluid injection, a prompt to observe and/or follow-up with the patient after the fluid injection, or any combination thereof;
obtain sensor data associated with the patient and determined after the fluid injection is started;
determine, based on the sensor data determined after the fluid injection is started, a current risk prediction for the patient associated with the fluid injection, wherein the current risk prediction includes a probability that the patient experiences the at least one adverse event in response to the fluid injection; and
provide, to the user device, the current risk prediction.

2. The system of claim 1 , wherein the at least one processor is further programmed and/or configured to:
automatically control, based on the current risk prediction, at least one of: (i) a fluid injection system to stop the fluid injection; and (ii) an imaging system to adjust a timing of an imaging operation.

3. The system of claim 1 , wherein the patient data includes at least one of the following parameters associated with the patient: an age; a gender; a weight; a prior chemotherapy status; an estimated glomerular filtration rate (eGFR); a thyroid stimulating hormone (TSH) level; a Triiodothyronine (FT3) Thyroxine (FT4) ratio (FT3/FT4); a level of an environmental influence; a prior reaction to a previous fluid injection status; an atopic disorder status; a medical status associated with at least one of diabetes and hypertension; a congestive heart failure status; a hematocrit level; a renal failure status; a malignancy status; an implanted device for a central venous access status; a type of a medication; a type of fluid media to be administered in the fluid injection; an injection protocol associated with a fluid injection; a type of an imaging exam; a flow rate associated with the fluid injection; a catheter gauge associated with the fluid injection; a total volume of fluid associated with the fluid injection; a pressure curve associated with the fluid injection, a pressure limit curve associated with a fluid injection, an injection site location associated with the fluid injection; or any combination thereof.

4. The system of claim 1 , wherein the sensor data includes at least one of the following parameters associated with the patient: a heart rate; a sound or vibration; a temperature; an oxygen saturation level; an electrocardiogram (ECG); a body fat/water-content ratio; a tissue impedance; a vessel distribution level; a vessel diameter; a hydration level; a hematocrit level; a skin resistivity; a blood pressure; a muscle tension level; a light absorptivity level; a motion level; an arm position; an arm circumference; a respiration rate; an amount of absorbed radiation; an electromyogram (EMG); a skin color; a surface vessel dilation amount; a bio-impedance; a light absorptivity; a hemoglobin level; an inflammation level; an environmental temperature of an environment surrounding the patient, a barometric pressure in the environment surrounding the patient; an ambient light level; an ambient sound level; or any combination thereof.

5. The system of claim 1 , further comprising:
at least one sensor configured to determine, after the fluid injection is started, the sensor data associated with the patient.

6. The system of claim 5 , wherein the at least one sensor is further configured to:
determine, after the fluid injection, the sensor data, and
wherein the at least one processor is further programmed and/or configured to:
determine, based on the sensor data determined after the fluid injection, the current risk prediction; and
provide, to the user device, after the fluid injection, the current risk prediction.

7. The system of claim 5 , wherein the at least one adverse event includes the extravasation, and wherein the at least one processor is further programmed and/or configured to provide the current risk prediction by automatically controlling, in response to determining that the patient experiences the extravasation, the fluid injection system to stop the fluid injection.

8. The system of claim 5 , wherein the at least one sensor includes at least one of: an image capture device; an accelerometer; a strain gauge; a global positioning system (GPS); a skin resistivity or conductance sensor; a heart rate monitor; a microphone; a thermal or temperature sensor; a pulse oximeter; a hydration sensor; a dosimeter; an ultrasound sensor; an acoustic sensor; one or more electrodes configured to measure at least one of a tissue impedance, an electromyogram (EMG), and an electrocardiogram (ECG); a microwave sensor; a mechanical impedance sensor; a chemical sensor; a force or pressure sensor; or any combination thereof.

9. A system comprising:
at least one sensor configured to determine, before a fluid injection associated with a patient is started, sensor data associated with the patient; and
at least one processor programmed and/or configured to:
obtain patient data associated with the patient; and
determine, based on the patient data and the sensor data, an initial risk prediction for the patient associated with the fluid injection to be administered to the patient, wherein the initial risk prediction includes a probability that the patient experiences at least one adverse event in response to the fluid injection, and wherein the at least one adverse event includes: an extravasation, a post-contrast acute kidney injury, an acute adverse event, a contrast media induced nephrotoxicity, and a thyrotoxicosis such that the initial risk prediction includes a probability that the patient experiences the extravasation, a probability that the patient experiences the post-contrast acute kidney injury, a probability that the patient experiences the acute adverse event, a probability that the patient experiences the contrast media induced nephrotoxicity, and a probability that the patient experiences the thyrotoxicosis; and
provide, to a user device, before the fluid injection is administered to the patient, the initial risk prediction, wherein the initial risk prediction further includes at least one of: a prompt to administer a medication to the patient before the fluid injection, a prompt to adjust an injection protocol for the fluid injection, a prompt to adjust an imaging protocol f

Assignees

• Bayer Healthcare Llc

Inventors

• Thuering Johannes Anton
• Uber Iii Arthur
• Griffiths David
• Mcdermott Michael
• Lang Charles
• Van Roosmalen Linda
• Skirble Barry
• Czibur Adam
• Moore Daniel
• Caruso Vincenzo
• Clarke Brandon

Classifications

• A61B5/0205 Primary

  Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title

• A61B5/7275

  Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor · CPC title

• A61M5/007

  for contrast media · CPC title

• A61M5/1723

  using feedback of body parameters, e.g. blood-sugar, pressure (measurement of body parameters A61B5/00) · CPC title